Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amsden, G. W.
Right arrow Articles by Hejmanowski, L. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amsden, G. W.
Right arrow Articles by Hejmanowski, L. G.
(Chest. 1999;116:115-119.)
© 1999 American College of Chest Physicians

A Randomized, Crossover Design Study of the Pharmacology of Extended-Spectrum Fluoroquinolones for Pneumococcal Infections*

Guy W. Amsden, PharmD; Danielle M. Graci, PharmD; Laura J. Cabelus, BSN and Linda G. Hejmanowski, BS

* From the Clinical Pharmacology Research Center (Drs. Amsden and Graci, and Ms. Cabelus), Bassett Healthcare, Cooperstown, NY; and the Analytical Division (Ms. Hejmanowski), Clinical Pharmacokinetics Laboratory, Buffalo, NY.

Correspondence to: Guy W. Amsden, PharmD, Clinical Pharmacology Research Center, Bassett Health-care, One Atwell Road, Cooperstown, NY 13326; e-mail: guy.amsden{at}bassett.org

Study objectives: The objectives of this study were to characterize the single-dose and steady-state plasma pharmacokinetics of IV levofloxacin and IV alatrofloxacin, and to compare the results to pneumococcal isolate sensitivities in order to estimate the clinical efficacy of current community-acquired pneumonia treatment regimens against pneumococcal infections.

Design: Two-way, open-label, randomized, crossover study.

Participants: Each of 12 healthy volunteer subjects received IV levofloxacin, 500 mg qd for 7 days, and IV alatrofloxacin, 200 mg qd for 7 days. The two regimens were separated by a 2-week washout period.

Measurements and results: Plasma concentration profiles were collected around the first and final doses of both regimens and were assayed for their respective quinolone concentrations. When the peak concentrations for both agents were compared to standard twofold dilution minimum inhibitory concentration (MIC) values for pneumococcal isolates, it was discovered that the breakpoint MIC value at which each compound would no longer achieve a peak plasma concentration/MIC ratio of at least 12:1 was 0.5 mg/L for levofloxacin and 0.25 mg/L for alatrofloxacin.

Conclusions: Based on the MIC that inhibits 90% of isolates of Streptococcus pneumoniae for both of these agents (1.0 to 2.0 mg/L for levofloxacin and 0.125 to 0.25 mg/L for trovafloxacin), our results indicate that although the once-daily regimen of alatrofloxacin appears to be appropriate for this pathogen, a more aggressive regimen may need to be investigated to optimize the clinical and microbiological effects of levofloxacin.

Key Words: alatrofloxacin • fluoroquinolone • levofloxacin • pneumococcus • quinolone • trovafloxacin






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.